metadata stringlengths 193 9.04k | data stringlengths 108 34.6k | criteria stringlengths 174 17.4k | __index_level_0__ int64 0 40.3k |
|---|---|---|---|
{
"NCT_ID" : "NCT01631318",
"Brief_Title" : "Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases",
"Official_title" : "Pilot Technical Feasibility Study on 3D Contrast-enhanced Ultrasound Imaging and to Assess Whether Change in Ultrasound 3D Perfusion Pattern Can Predict Tre... | #Study Description
Brief Summary
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics c... | #Eligibility Criteria:
Inclusion Criteria
* Provides written Informed Consent and is willing to comply with protocol requirements.
* Has at least 1 focal lesion in liver or kidney
* Patient may be (i) in the process of receiving treatment (1 scan session), (ii) never treated (3 scan sessions) or (iii) changing treatme... | 18,949 |
{
"NCT_ID" : "NCT00615446",
"Brief_Title" : "A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors",
"Official_title" : "A Phase 1 Study Of SU011248 And Gemcitabine In Patients With Advanced Solid Tumors",
"Conditions" : ["Solid Tumors"],
"Interventions... | #Study Description
Brief Summary
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors
#Intervention
- DRUG : SU011248; Gemcitabine
- Dose finding study using SU011248 (sunitinib) daily by oral capsu... | #Eligibility Criteria:
Inclusion Criteria:
* Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists
* Patient has good performance status (ECOG 0 or 1)
Exclusion Criteria:
* Prior treatment with either gemcitabine or SU011248
* Hypertension that ... | 17,239 |
{
"NCT_ID" : "NCT00507273",
"Brief_Title" : "Gastrointestinal Stromal Tumors (GIST) Registry",
"Official_title" : "Gastrointestinal Stromal Tumors (GIST) Registry Protocol: reGISTry",
"Conditions" : ["Gastrointestinal Stromal Tumors"],
"Interventions" : ["Other: GIST Registry"],
"Location_Countries" : ["United Stat... | #Study Description
Brief Summary
The goal of this observational research study is to establish a registry of information regarding how different physicians treat and manage patients with gastrointestinal stromal tumors (GISTs).
Objectives:
1. To describe variation in management of patients with GIST, overall and by... | #Eligibility Criteria:
Inclusion Criteria:
* All patients who have been diagnosed with GIST are eligible for enrollment.
Exclusion Criteria:
* Patients with a histologic diagnosis other than gastrointestinal stromal tumor (GIST).
Sex :
ALL
Ages :
- Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADU... | 130 |
{
"NCT_ID" : "NCT00614835",
"Brief_Title" : "Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus",
"Official_title" : "A Pilot Study of Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus",
"Conditions" : [... | #Study Description
Brief Summary
This is a pilot study of adjuvant therapy for patients with leiomyosarcoma of the uterus that has been completely removed by surgery. 'Adjuvant' therapy means that the tumor (the leiomyosarcoma) has been completely removed by surgery; thus, giving further treatment now is done in hope... | #Eligibility Criteria:
Inclusion Criteria:
* Pathologically confirmed leiomyosarcoma of the uterus, completely resected, stage I, II, III or IV within 8 weeks of surgery to remove the tumor(s). Patients with stage I tumors should have LMS that is considered high-grade by histology.
* No prior chemotherapy for LMS
* No... | 14,243 |
{
"NCT_ID" : "NCT04600336",
"Brief_Title" : "Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer",
"Official_title" : "A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men R... | #Study Description
Brief Summary
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer . Androgen deprivation therapy decreases testosterone and other androgens through medications or s... | #Eligibility Criteria:
Inclusion Criteria:
* Men who are currently receiving androgen deprivation therapy (ADT) for the treatment of prostate cancer. ADT is defined by a history of orchiectomy, or ongoing usage of gonadotropin-releasing hormone agonists or antagonists. Men receiving abiraterone, but not enzalutamide, ... | 20,168 |
{
"NCT_ID" : "NCT03176381",
"Brief_Title" : "Tissue Predictors of Abiraterone Benefit",
"Official_title" : "Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC",
"Conditions" : ["Metastatic Castration-resistant Prostate Cancer"],
"Location_Countries" : ["China"],
"Study_Design" : {
"Study_Type... | #Study Description
Brief Summary
This is an observational, prospective (study following participants forward in time), multi-center (study conducted in more than 1 center) study to identify the predictive factors that will effectively predict the response to abiraterone treatment in metastatic castration-resistant pr... | #Eligibility Criteria:
Inclusion Criteria:
* Participants who have given consent form;
* Patients with a confirmed diagnosis of mCRPC according to EAU 2017 guideline;
* Serum testosterone must reach castration level: <50 ng per deciliter;
* Participants with life expectancy of at least 6 months based on the Investigat... | 23,502 |
{
"NCT_ID" : "NCT01267110",
"Brief_Title" : "Engaging Diverse Underserved Communities to Bridge the Mammography Divide",
"Official_title" : "Engaging Diverse Underserved Communities to Bridge the Mammography Divide",
"Conditions" : ["Breast Cancer Screening"],
"Interventions" : ["Other: Control", "Other: MI2 interve... | #Study Description
Brief Summary
Breast cancer is the second most common cause of cancer death in the U.S.1 in spite of being preventable, easily detectable, and curable.2-11 Breast screening continues to be underutilized by the general population and especially by traditionally underserved minority populations. Two ... | #Eligibility Criteria:
Inclusion Criteria:
* Latina or AI/AN woman residing in one of participating communities
* Aged >=40 years
* Not up to date on mammography screening
* Home address & access to a working telephone
* Responded to 120-day post randomization follow-up call
Exclusion Criteria:
* Receipt of mammogra... | 16,776 |
{
"NCT_ID" : "NCT03016728",
"Brief_Title" : "Physical Activity for Adolescent and Young Adult Cancer Survivors",
"Official_title" : "Exploring the Feasibility, Safety, and Potential Benefits of a 12-week Home-based Physical Activity Intervention",
"Conditions" : ["Adolescent and Young Adult Cancer Survivors"],
"Inte... | #Study Description
Brief Summary
More adolescents and young adults are surviving cancer than ever before. Many endure negative effects related to their cancer and its treatment, which reduces their quality of life and functioning. Physical activity is one strategy that has been shown to promote quality of life amongs... | #Eligibility Criteria:
INCLUSION CRITERIA:
* Have been diagnosed with cancer for the first time between the ages of 15 and 39 years;
* Have completed cancer treatment within 5 years;
* Currently between the ages of 15 <= age <= 44;
* Have no current evidence of progressive disease, secondary cancer (i.e., cancer cells... | 36,315 |
{
"NCT_ID" : "NCT00614978",
"Brief_Title" : "Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer",
"Official_title" : "Phase 1 Study of the Combination of Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer",
"... | #Study Description
Brief Summary
Objectives:
Primary - Determine the maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLT) of combining lapatinib and temozolomideSecondary - Obtain preliminary information on the clinical anti-tumor activity of lapatinib plus temozolomide on brain metastases se... | #Eligibility Criteria:
Inclusion Criteria:
* 18 - 70 years
* Women with cytologically or histologically proven metastatic breast cancer with recurrent / progressive brain metastases evaluable by MRI, after standard treatment with surgery (at least 3 weeks prior) or WBRT (at least 3 weeks prior) or stereotactic RT (at ... | 34,307 |
{
"NCT_ID" : "NCT05911373",
"Brief_Title" : "Serratus Plane Block Versus Serratus Plane Block Plus Parasternal Block Combination for Breast Surgery",
"Official_title" : "Serratus Plane Block Versus Serratus Plane Block Plus Parasternal Block on Postoperative Opioid Consumption and Dermatomal Analyses for Breast Surger... | #Study Description
Brief Summary
Mastectomy is a technique often used in breast cancer surgery. Patients experience moderate to severe pain postoperatively after this procedure. Various plane blocks, NSAIDs, and opioid analgesics can be administered to these patients as components of multimodal analgesia. In the the ... | #Eligibility Criteria:
Inclusion Criteria:
* American Society of Anesthesiologist's physiologic state I-III patients
* To undergo Mastectomy Surgery
* Being between the ages of 18 <= age <= 65 years
Exclusion Criteria:
* Having a known heart, kidney, liver or hematological disease
* Having a history of peptic ulcer,... | 4,844 |
{
"NCT_ID" : "NCT02379247",
"Brief_Title" : "BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer",
"Official_title" : "Phase I/II Study of BYL719 and Nab-Paclitaxel in Subjects With Locally Recurrent or Metastatic HER-2 Negative Breast Cancer",
"Conditions" : ["Breast Cancer"],
... | #Study Description
Brief Summary
Investigate the use of BYL719 (alpelisib) as combination therapy with Nab-Paclitaxel in locally recurrent or metastatic HER-2 negative breast cancer.
Detailed Description
Breast cancer is the most common cancer and the second leading cause of cancer related death in American women. ... | #Eligibility Criteria:
Inclusion Criteria:
* Ability to understand and the willingness to sign a written Informed Consent Form.
* Age >= 18 years
* Histologically proven HER-2 negative breast cancer (HER-2 negative defined as HER IHC 0 or 1+ and/or HER-2 FISH negative); HER-2 negative breast cancer includes hormone po... | 37,829 |
{
"NCT_ID" : "NCT03052907",
"Brief_Title" : "Breast Screening & Patient Navigation (BSPAN2): Evaluating a De-Centralized Regional Delivery System for Rural Underserved",
"Official_title" : "Breast Screening & Patient Navigation (BSPAN2): Evaluating a De-Centralized Regional Delivery System for Rural Underserved",
"Co... | #Study Description
Brief Summary
The investigators will expand BSPan's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/uTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. The in... | #Eligibility Criteria:
Inclusion Criteria:
Inclusion criteria for patient participants include:
* adult females age 40 <= age <= 64,
* able to read, speak and comprehend English or Spanish,
* the capacity to comprehend study information, and
* ability to communicate with voice (to participate in interviews).
Inclusi... | 31,323 |
{
"NCT_ID" : "NCT00572923",
"Brief_Title" : "Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans",
"Official_title" : "Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans",
"Conditions" : ["Small Cell Lun... | #Study Description
Brief Summary
Our group has shown that the omission of elective nodal irradiation on the basis of CT scans in patients with LD-SCLC lead to a higher than expected isolated nodal recurrence in the ipsilateral supraclavicular area. We have previously also shown that selective mediastinal nodal radiat... | #Eligibility Criteria:
Inclusion Criteria:
* Histological or cytological proven SCLC
* UICC stage I-III, 'limited disease'
* Performance status 0 <= age <= 2
* FeV 1 and DLCO at least 30% of the age-predicted value
Exclusion Criteria:
* Not SCLC or mixed SCLC and other histologies (e.g. non-small cell lung carcinoma... | 21,176 |
{
"NCT_ID" : "NCT04297007",
"Brief_Title" : "Pectoral Nerve Block Type-II and Rhomboid Intercostal Block for Pain Management Following Mastectomy Surgery",
"Official_title" : "Comparison of Ultrasound-Guided Type-II Pectoral Nerve Block and Rhomboid Intercostal Block for Pain Management Following Mastectomy Surgery",
... | #Study Description
Brief Summary
Postoperative pain is an important issue in patients underwent mastectomy and axillary dissection surgery. Postoperative effective pain treatment provides early mobilization and shorter hospital stay. The US-guided pectoral nerve block (PECS) may be used for postoperative pain treatme... | #Eligibility Criteria:
Inclusion Criteria:
* American Society of Anesthesiologists (ASA) classification I-II
* Scheduled for mastectomy and axillary dissection surgery under general anesthesia
Exclusion Criteria:
* history of bleeding diathesis,
* receiving anticoagulant treatment,
* known local anesthetics and opio... | 33,749 |
{
"NCT_ID" : "NCT03489057",
"Brief_Title" : "Efficacy of a Couple-Focused mHealth Symptom Self-management Program",
"Official_title" : "Testing the Efficacy of a Couple-Focused, Tailored mHealth Intervention for Symptom Self-Management Among Men With Prostate Cancer and Their Partners",
"Conditions" : ["Prostate Canc... | #Study Description
Brief Summary
In this study, the investigators propose to test the efficacy of a couple-focused, web-based tailored prostate cancer symptom management program, Prostate Cancer Education and Resources for Couples (PERC) in a randomized clinical trial. A two-group (PERC versus National Cancer Institu... | #Eligibility Criteria:
Inclusion Criteria:
The eligible patients must
* be 40 <= age <= 75 of age
* be within 16 weeks (4 months) after completing initial treatment for localized prostate cancer as confirmed by patient and biopsy pathology report) with curative intent, i.e., surgery or radiotherapy +/- hormonal treat... | 2,726 |
{
"NCT_ID" : "NCT02241499",
"Brief_Title" : "Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.",
"Official_title" : "Palliative Short-course Hypofractionated Radiotherapy Followed by ... | #Study Description
Brief Summary
In this trial, patients with histologically proven adenocarcinoma of the esophagus or esophagogastric junction noneligible for surgery or chemoradiation with curative intent will be included. Primary objective is to determine the rate of improvement in dysphagia after palliative short... | #Eligibility Criteria:
Inclusion Criteria:
* Patients with histologically proven adenocarcinoma of the esophagus or esophagogastric junction noneligible for surgery or chemoradiation with curative intent
* Any T, N and M
* Age: >= 18 years
* WHO performance status <= 2
* Life expectancy > 3 months
* Dysphagia score > ... | 26,126 |
{
"NCT_ID" : "NCT02293642",
"Brief_Title" : "Bone Pain Score Validation Initiative",
"Official_title" : "Prospective Epidemiology Study to Validate the BOMET-QoL-10 in Patients With Bone Metastasis in Germany",
"Conditions" : ["Bone Metastasis"],
"Location_Countries" : ["Germany"],
"Study_Design" : {
"Study_Type" :... | #Study Description
Brief Summary
Translation and validation of the BOMET-QoL-10 questionnaire in Germany and assessment of its validity and responsiveness.
Detailed Description
Aim of this study is to translate the questionnaire and to examine the psychometric properties of BOMET-QoL-10 in a German population. Corr... | #Eligibility Criteria:
Inclusion Criteria:
* Male or female adults patients (>= 18 years)
* Diagnosed cancer of the breast, kidney, lung or prostate
* Bone metastases
* Estimated life expectancy of at least 6 months
* Fluent German speaking, reading and writing
* Informed written consent
Exclusion Criteria:
* Patien... | 24,651 |
{
"NCT_ID" : "NCT01658241",
"Brief_Title" : "Panobinostat Biological Correlates Study",
"Official_title" : "A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy",
"Conditions" : ["Nodal Lymphoma", "Lymphoma With Cutaneous Involvement", "Lymphoma in Le... | #Study Description
Brief Summary
This study is looking at the effects of Panobinostat, an investigational treatment, on cancer cells in patients who have Hodgkin lymphoma (a cancer of the immune system with specific Hodgkin/Reed Sternberg Cells), T-cell lymphoma (a cancer of the immune system with too many T lymphocy... | #Eligibility Criteria:
Inclusion Criteria:
* Histologically proven lymphoproliferative neoplasm belonging to one of the following disease categories that has relapsed or has an incomplete response to conventional therapy, or where the patient is considered intolerant to conventional chemotherapy or where no other conv... | 15,603 |
{
"NCT_ID" : "NCT03765996",
"Brief_Title" : "Effectiveness of Taping on Anastomotic Regions in Patients With Breast Cancer-Related Lymphoedema",
"Official_title" : "Effectiveness of Kinesio® Taping on Anastomotic Regions in Patients With Breast Cancer-Related Lymphoedema: A Randomized Controlled Study",
"Conditions" ... | #Study Description
Brief Summary
One of the most common conservative treatments of lymphoedema is Complex Decongestive Physiotherapy (CDP). The bandage is one of the most important components of the treatment process. The multilayer short-stretch bandage is used to maintain volume reduction and prevent lymph backflow... | #Eligibility Criteria:
Inclusion Criteria:
* Patients who had unilateral BCRL and women aged over 18 who were 'significant', 'marked', or 'severe' lymphoedema.
Exclusion Criteria:
* Patients with paralysis on part of the affected arm,
* Patients who had undergone CDP more than once within six months,
* Patients who ... | 9,162 |
{
"NCT_ID" : "NCT01947530",
"Brief_Title" : "Study Using Combined Virtual 4-D Electromagnetic (EM) Tip-Tracked Devices & EBUS in Diagnosis of Lung Nodules",
"Official_title" : "Pilot Study Using Combined Virtual 4-D EM Tip-Tracked Devices and Endobronchial Ultrasound (EBUS)in the Diagnosis of Peripheral Pulmonary Nodu... | #Study Description
Brief Summary
The purpose of this study is to determine the safety and biopsy yield of EM Tip Tracked devices compared to standard bronchoscopy.
#Intervention
- PROCEDURE : Navigational Bronchoscopy
- Other Names :
- 4-D EM Tip-tracked Devices, Veran Navigational System
- PROCEDURE : Standard... | #Eligibility Criteria:
Inclusion Criteria:
* Any adult patient aged 18 and older, able to sign an informed consent and is scheduled for flexible bronchoscopy with biopsies of peripheral nodules. Patient needs to have a recent chest CAT scan within last 4 weeks or will obtain a chest CAT scan prior to bronchoscopy.
Ex... | 8,122 |
{
"NCT_ID" : "NCT05300828",
"Brief_Title" : "Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer",
"Official_title" : "An Observational Study to Evaluate the Safety of the Combination Therapy of Genexol PM and Carboplatin as First-line Therapy for Ovarian Cancer Patients",
"Conditions" : ["Ov... | #Study Description
Brief Summary
To evaluate the safety profile of Genexol PM combination with carboplatin for patients with newly diagnosed ovarian cancer. We hypothesized Genexol PM can be safely administered to newly diagnosed ovarian cancer patients compared to conventional paclitaxel/carboplatin combination ther... | #Eligibility Criteria:
Inclusion Criteria:
* Age over 18
* Patients consented to participate
* Pathologically diagnosed ovarian cancer FIGO stage IC-IVB
* ECOG 0 <= age <= 2
* Patients with an expected survival of 3 months or more
Exclusion Criteria:
* History of paclitaxel or carboplatin hypersensitivity
* Inadequa... | 36,157 |
{
"NCT_ID" : "NCT02677142",
"Brief_Title" : "Evaluating the Efficacy of a Group Social Skills Intervention",
"Official_title" : "A Randomized Control Trial to Evaluate the Efficacy of a Group Social Skills Intervention for Childhood Survivors of Brain Tumours",
"Conditions" : ["Brain Tumours"],
"Interventions" : ["B... | #Study Description
Brief Summary
Tumours affecting the brain are a very heterogeneous group of diseases. Accordingly, treatment strategies vary widely depending on child's age, tumour location, its resectability and histology. As a group, however, the survival rate of childhood brain tumors has improved in recent yea... | #Eligibility Criteria:
Inclusion Criteria:
* Diagnosed with a brain/spinal tumour
* off treatment for at least 3 months or on maintenance chemotherapy but medically stable, e.g., low grade gliomas
* between 8 and 16 years at the time of enrollment
* have sufficient fluency in English for active group participation
* a... | 26,127 |
{
"NCT_ID" : "NCT02924025",
"Brief_Title" : "Motivational Interviewing as an Intervention for PCOS",
"Official_title" : "Motivational Interviewing as an Intervention for Women With Polycystic Ovary Syndrome and BMI Above 30 kg/m2",
"Conditions" : ["Polycystic Ovary Syndrome", "Overweight and Obesity", "Motivation"],
... | #Study Description
Brief Summary
The aim of the study is to examine if motivational interviewing can have a positive effect on weight loss over a 6 month period. By losing weight, the investigators assume the patients will have a positive effect on quality of life, and also that weight loss will help to regulate the ... | #Eligibility Criteria:
Inclusion Criteria:
* Women with polycystic ovary syndrome and BMI above 30 kg/m2
Exclusion Criteria:
* Women taking gender hormone medication, for example birthcontrol pills.
* Metformin treatment in less than 3 months (i.e. women who is in a stable treatment and have been taking metformin in... | 12,591 |
{
"NCT_ID" : "NCT01226550",
"Brief_Title" : "Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan",
"Official_title" : "Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cyto... | #Study Description
Brief Summary
This is an open, non-randomized, phase I-II, pilot study, which evaluates the combination of optimum cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy (HIPEC) with mitomycin C (MMC) and irinotecan. The latter drug will be administered in escalating doses to... | #Eligibility Criteria:
Inclusion Criteria:
* Patients with a peritoneal carcinosis (PC) either of digestive origin or primary: a colorectal or gastric carcinosis, a peritoneal pseudomyxoma or mesothelioma, or a primary carcinosis of the peritoneum regardless the number of prior treatment lines.
* A PC and primary tumo... | 23,721 |
{
"NCT_ID" : "NCT03336762",
"Brief_Title" : "Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis",
"Official_title" : "Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis",
"Conditions" : ["Transverse Myelitis"],
"Location_Countries" : ["United Kingdom"],
"Study_Design" : {
"Study_Ty... | #Study Description
Brief Summary
ISCoPE-TM will use intra spinal monitoring techniques to assess cord perfusion and metabolism in patients with severe spinal cord damage from transverse myelitis
Detailed Description
Transverse myelitis (TM) is a rare inflammatory condition of the spinal cord. It is characterised by... | #Eligibility Criteria:
Inclusion Criteria:
* Transverse myelitis (as defined by TM working group 2002)
* MRI evidence of swollen enlarged spinal cord. Defined as a larger cord diameter compared to the adjacent normal signal intensity spinal cord, with loss of cerebrospinal fluid space between cord and dura mater.
* Ag... | 12,496 |
{
"NCT_ID" : "NCT01398462",
"Brief_Title" : "Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients",
"Official_title" : "A Phase I Clinical Study of CWP232291 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome Having Failed Hyp... | #Study Description
Brief Summary
CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage. CWP232291 targets beta-catenin for degradation and thereby inhi... | #Eligibility Criteria:
Inclusion Criteria:
* Able to understand and willing to sign an informed consent form (ICF) prior to initiation of any study-specific procedure and treatment
* 18 years
* 3. A pathologically confirmed diagnosis of AML or CMML-2 by World Health Organization (WHO) classification that is relapsed o... | 12,528 |
{
"NCT_ID" : "NCT04771988",
"Brief_Title" : "Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis",
"Official_title" : "Trans-arterial Radioembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis",
"Conditions" : ["Hepatocellular Carcinoma"],
"Study_Des... | #Study Description
Brief Summary
In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT), Sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (TARE) with yttrium-90 has been also proposed. A considerable percentage of such patients are no... | #Eligibility Criteria:
Inclusion Criteria:
* diagnosis of HCC;
* age >= 18 years;
* performance status according to Eastern Cooperative Oncology Group 0 <= age <= 1;
* preserved liver function (Child-Pugh score <=B7);
* PVTT limited to the first order portal branch.
Exclusion Criteria:
* any contraindication to TARE... | 33,183 |
{
"NCT_ID" : "NCT03783871",
"Brief_Title" : "NeuWave HCC China Study",
"Official_title" : "A Single-Arm, Prospective, Multicenter Study to Evaluate the Safety and Effectiveness of the NeuWave Certus Microwave Ablation System in Chinese Patients With Hepatocellular Carcinoma",
"Conditions" : ["Liver Tumor", "Hepatocel... | #Study Description
Brief Summary
This is a single-arm, prospective, multicenter, study. Individuals who are assessed for microwave (MW) ablation of HCC in accordance with their institution's standard of care (SOC), who meet study entry criteria and sign the informed consent, will be enrolled. The patients will be tre... | #Eligibility Criteria:
Inclusion Criteria:
* Diagnosed primary or recurrent HCC determined in accordance with the institution's SOC procedure, a single tumor size up to 5 cm or a maximum of 3 tumors up to 3 cm per tumor. Tumor size must be measured with at least 2-dimensional (2D) imaging.
* Scheduled for microwave ab... | 32,236 |
{
"NCT_ID" : "NCT01991457",
"Brief_Title" : "Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia",
"Official_title" : "Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fluda... | #Study Description
Brief Summary
The goal of this research is to test if the conditioning regimen, fludarabine and total body irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment regimen for ALL patients older than 40 years of age and/or younger patients with high risk medical c... | #Eligibility Criteria:
Inclusion Criteria:
* Disease Criteria:
* ALL in complete remission (CR) at the time of transplant. Remission is defined as 'less than 5.0% bone marrow lymphoblasts by morphology,' as determined by a bone marrow aspirate obtained within 2 weeks of study registration.
* Philadelphia chromoso... | 2,834 |
{
"NCT_ID" : "NCT04299048",
"Brief_Title" : "Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.",
"Official_title" : "A PHASE 1B, 12-WEEK, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING... | #Study Description
Brief Summary
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
Detailed Description
This 12-week open-label study will explore how PF-06946860 is tolerated, the effects of the study drug, the best dose for treatment... | #Eligibility Criteria:
Inclusion Criteria:
* Documented histologic or cytologic diagnosis of advanced metastatic NSCLC, advanced/unresectable pancreatic cancer, or metastatic colorectal cancer.
* Cachexia, defined by BMI <20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening or Involuntary we... | 8,279 |
{
"NCT_ID" : "NCT01165671",
"Brief_Title" : "Carbon Ion Radiotherapy for Primary Glioblastoma",
"Official_title" : "Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary... | #Study Description
Brief Summary
Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons. Using this treatment regimen, overall survival could be extended significantly however, median overa... | #Eligibility Criteria:
Inclusion Criteria:
* histologically confirmed unifocal, supratentorial primary glioblastoma
* macroscopic tumor after biopsy or subtotal resection
* indication for combined radiochemotherapy with temozolomide
* prior photon irradiation of 48 <= age <= 52 Gy to the T2-hyperintense area, resectio... | 32,406 |
{
"NCT_ID" : "NCT01326000",
"Brief_Title" : "A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer",
"Official_title" : "A Randomized, Multicenter, Open-label Phase II Study of RO5083945 in Combination With... | #Study Description
Brief Summary
This randomized, multicenter, open label study will evaluate the safety and efficacy of RO5083945 in combination with FOLFIRI as compared to FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with metastatic colorectal cancer. Patients will be randomized to r... | #Eligibility Criteria:
Inclusion Criteria:
* Adult patients, >= 18 years
* Carcinoma of the colon and/or rectum
* Disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease
* ECOG performance status 0 <= age <= 1
* Adequate hematological, ... | 27,440 |
{
"NCT_ID" : "NCT01747889",
"Brief_Title" : "Objective and Subjective Outcomes of an Electronic Chest Drainage System",
"Official_title" : "Objective and Subjective Outcomes of an Electronic Chest Drainage System Versus Traditional Devices: a Randomized Comparison",
"Conditions" : ["Lung Cancer"],
"Interventions" : ... | #Study Description
Brief Summary
This study is designed to compare the Thopaz chest tube drainage system to the traditional collection chamber system. The Thopaz system is already in clinical use in the United States and throughout the world. As such, this study is not evaluating safety or efficacy of this system bot... | #Eligibility Criteria:
Inclusion Criteria:
* Able and willing to read, understand, and provide written Informed Consent
* Age range of 18 <= age <= 90 years
* Patients undergoing a segmentectomy, lobectomy, or bilobectomy. Both open and minimally invasive (thoracoscopic or robotic) resections are acceptable.
Exclusio... | 5,822 |
{
"NCT_ID" : "NCT00390715",
"Brief_Title" : "Treatment of Acute Myeloblastic Leukemia in Younger Patients",
"Official_title" : "Prospective Study of the Value of the Cytogenetic and of the Monitoring of the Minimal Residual Disease",
"Conditions" : ["Acute Myeloblastic Leukemia"],
"Location_Countries" : ["Spain"],
... | #Study Description
Brief Summary
study of the value of the cytogenetics and the monitoring of the residual minimum disease in the standard treatment of acute myeloblastic leukemia.
Detailed Description
The treatment scheme is purely welfare and therefore it does not require any approval of ethical committees for hi... | #Eligibility Criteria:
Inclusion Criteria:
* Age< or =65 years.
* ECOG<=3.
* AML of new diagnose.
* Consent for chemotherapy.
Sex :
ALL
Ages :
- Maximum Age : 65 Years
- Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT, CHILD
Accepts Healthy Volunteers:
No
| 28,150 |
{
"NCT_ID" : "NCT00054886",
"Brief_Title" : "Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer",
"Official_title" : "Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma",
"Conditions" : ["Kidney Neoplasms"],
... | #Study Description
Brief Summary
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
#Intervention
- DRUG : SU-011,248 | #Eligibility Criteria:
Inclusion Criteria:
* Eligible patients must be at least 18 years with a diagnosis of metastatic kidney cancer.
* The patient's kidney cancer must have gotten worse during/after previous cytokine-based therapy was given.
* Any side effects from prior therapy must have subsided, and blood and uri... | 19,305 |
{
"NCT_ID" : "NCT03399552",
"Brief_Title" : "Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma",
"Official_title" : "An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)",
"Conditions" : ["Malignant Mesothelioma (MPM)"],
"Intervention... | #Study Description
Brief Summary
The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiation therapy on the immune system. It is ... | #Eligibility Criteria:
Inclusion Criteria:
* Patient willing and able to provide written informed consent for the trial.
* Patient age >= 18 at time of consent.
* Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma (MPM).
* No plans for surgical resection.
* At least one prior line o... | 27,373 |
{
"NCT_ID" : "NCT05485896",
"Brief_Title" : "Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC",
"Official_title" : "A Prospective Single-arm Clinical Study of Pembrolizumab Combined With Lenvatinib Neoadjuvant Therapy in Patients With Advanced Renal Cell Carcinoma",
"Conditions" : ["Renal Cell Car... | #Study Description
Brief Summary
This is a phase II study to determine the efficacy and safety of Pembrolizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer. Further evaluate whether the treatment plan is beneficial to the patient's surgery.
Detailed Description... | #Eligibility Criteria:
Inclusion Criteria:
* Willing and able to provide written informed consent;
* Age >= 18 years and age <=75years;
* Patients with pathologically and radiographically confirmed clear cell renal cell carcinoma with clinical staging: cTanyN1Many, cTanyNanyM1, cT3 <= age <= 4NanyMany, and all visible... | 13,259 |
{
"NCT_ID" : "NCT03733210",
"Brief_Title" : "Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer",
"Official_title" : "Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and... | #Study Description
Brief Summary
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indi... | #Eligibility Criteria:
Inclusion Criteria:
* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
* Subjects diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Subjects with recurrent disease or a new primary will be allowed.
* Plan... | 22,163 |
{
"NCT_ID" : "NCT01443078",
"Brief_Title" : "Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)",
"Official_title" : "Phase II Trial of Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable ... | #Study Description
Brief Summary
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.
It is routine to give chemotherapy prior to surgery in patients ... | #Eligibility Criteria:
Inclusion Criteria:
* Pathologic confirmation of NSCLC at MSKCC
* Stages IB, IIA, IIB, IIIA or IIIB NSCLC
* Primary tumor must measure >= 2 cm on CT imaging (per PERCIST guidelines)
* Primary tumor must be FDG-avid with an SUVmax >4.5 (to be consistent with PERCIST guidelines)
* Patients must be... | 32,202 |
{
"NCT_ID" : "NCT01501903",
"Brief_Title" : "Standard Versus Fanning Techniques for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA)",
"Official_title" : "Randomized Trial Comparing the Standard and Fanning Techniques for Fine Needle Aspiration of Pancreatic Mass Lesions at Endoscopic Ultrasound",
"Conditions" ... | #Study Description
Brief Summary
Endoscopic Ultrasound (EUS)-guided biopsy is the most ideal technique for evaluating a growth in the pancreas. EUS-guided biopsies yield a definitive diagnosis in greater than 80% of cases. In 15-20% of the cases, a definitive diagnosis cannot be made despite multiple attempts. One of... | #Eligibility Criteria:
Inclusion Criteria:
* Age > 19 years
* Solid Pancreatic Mass Lesions
Exclusion Criteria:
* Age < 19 years
* Coagulopathy
* Unable to consent
Sex :
ALL
Ages :
- Minimum Age : 19 Years
- Maximum Age : 90 Years
- Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT
... | 29,939 |
{
"NCT_ID" : "NCT05915221",
"Brief_Title" : "Effect of SMS Use on Postoperative Respiratory and Cough Exercise Compliance",
"Official_title" : "Effect of SMS Reminder Use on Postoperative Respiratory and Cough Exercise Compliance of Patients After Lung Cancer Surgery",
"Conditions" : ["Pulmonary Cancer", "Surgery"],
... | #Study Description
Brief Summary
Aim: This randomized controlled trial study aimed to evaluate the effect of SMS use on compliance with postoperative breathing and coughing exercises and patient satisfaction in patients undergoing pulmonary lobectomy for lung cancer surgery.
Material and methods: In the study, 62 pa... | #Eligibility Criteria:
Inclusion Criteria:
* undergoing elective pulmonary lobectomy,
* having preoperative normal lung capacity (pulmonary function test result FEV1/FVC >70%),
* being compatible with the use of triflow, undergoing pulmonary lobectomy for the first time,
* volunteering to participate in the study,
* h... | 28,389 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 10